Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P07237

UPID:
PDIA1_HUMAN

ALTERNATIVE NAMES:
Cellular thyroid hormone-binding protein; Prolyl 4-hydroxylase subunit beta; p55

ALTERNATIVE UPACC:
P07237; B2RDQ2; P30037; P32079; Q15205; Q6LDE5

BACKGROUND:
The multifunctional Protein disulfide-isomerase, known alternatively as Cellular thyroid hormone-binding protein, Prolyl 4-hydroxylase subunit beta, and p55, is integral to cellular processes involving disulfide bond modification. It exhibits dual roles, acting as a chaperone to prevent protein aggregation and as a structural component in various enzymes. Its interaction with LGALS9 at the Th2 T helper cells' surface underscores its significance in cell migration and immune response.

THERAPEUTIC SIGNIFICANCE:
Linked to Cole-Carpenter syndrome 1, a disorder with osteogenesis imperfecta-like symptoms and craniosynostosis, Protein disulfide-isomerase's genetic variants highlight its therapeutic potential. Exploring its function further could lead to innovative treatments for this and related conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.